Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
Vemurafenib is approved for the treatment of metastatic melanoma in patients with BRAF V600 mutation. In pivotal clinical trials, BRAF testing has always been done with the approved cobas 4800 BRAF test. In routine practice, several methods are available and are used according to the laboratories us...
Main Authors: | Samia Mourah, Marc G Denis, Fabienne Escande Narducci, Jérôme Solassol, Jean-Louis Merlin, Jean-Christophe Sabourin, Jean-Yves Scoazec, L'Houcine Ouafik, Jean-François Emile, Remy Heller, Claude Souvignet, Loïc Bergougnoux, Jean-Philippe Merlio |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4366252?pdf=render |
Similar Items
-
The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01) -
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01) -
The role of BRAF(V600E) mutation in the pathogenesis of ameloblastoma
by: Bo-Cheng Chen, et al.
Published: (2018) -
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
by: Muna Al Hashmi, et al.
Published: (2020-05-01) -
Amelanotic melanoma presenting with plasmacytoid morphology and BRAF V600 mutation
by: Linda Kocovski, et al.
Published: (2015-06-01)